This article is a correction to:
Identification of ACKR4 as an immune checkpoint in pulmonary arterial hypertension
Chen-Yu Jiang1,2†
Li-Wei Wu1,2†
Yi-Wei Liu1,2
Bei Feng1,2
Lin-Cai Ye1,2
Xu Huang1,2
Yang-Yang He3
Yi Shen1,2
Yi-Fan Zhu1,2Xing-Liang Zhou1,2Dai-Ji Jiang1,2
Hai-Kun Qi4*‡
Hao Zhang1,2*‡
Yi Yan1,2*‡- 1Shanghai Clinical Research Center for Rare Pediatric Diseases, Shanghai Children’s Medical Center (SCMC), School of Medicine, Shanghai Jiao Tong University, Shanghai, China
- 2Heart Center and Shanghai Institute of Pediatric Congenital Heart Disease, Shanghai Children’s Medical Center (SCMC), School of Medicine, Shanghai Jiao Tong University, Shanghai, China
- 3School of Pharmacy, Henan University, Kaifeng, Henan, China
- 4School of Biomedical Engineering, Shanghaitech University, Shanghai, China
A Corrigendum on
Identification of ACKR4 as an immune checkpoint in pulmonary arterial hypertension
By Jiang C-Y, Wu L-W, Liu Y-W, Feng B, Ye L-C, Huang X, He Y-Y, Shen Y, Zhu Y-F, Zhou X-L, Jiang D-J, Qi H-K, Zhang H and Yan Y (2023) Front. Immunol. 14:1153573. doi: 10.3389/fimmu.2023.1153573
In the original article, there was a mistake in the Funding statement as published. The Projects of National Natural Science Foundation of China (82200065, 82000064) were wrong. The correct Funding statement appears below.
FUNDING
“This work was supported by the Project of National Natural Science Foundation of China (U20A2018), the Project of Shanghai Municipal Science and Technology Commission (20MC1920400), the National Key Research and Development Program of China (2022YFC2703102), Projects of National Natural Science Foundation of China (82200065, 82241007), Shanghai Pujiang Program (22PJ1410100), Young Talent Program of Shanghai Municipal Health Commission (2022YQ070) and Innovative research team of high-level local universities in Shanghai.”
The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Keywords: pulmonary arterial hypertension, atypical chemokine receptor 4, transcriptomics, chemokines, immune
Citation: Jiang C-Y, Wu L-W, Liu Y-W, Feng B, Ye L-C, Huang X, He Y-Y, Shen Y, Zhu Y-F, Zhou X-L, Jiang D-J, Qi H-K, Zhang H and Yan Y (2024) Corrigendum: Identification of ACKR4 as an immune checkpoint in pulmonary arterial hypertension. Front. Immunol. 15:1382832. doi: 10.3389/fimmu.2024.1382832
Received: 06 February 2024; Accepted: 07 February 2024;
Published: 20 February 2024.
Approved by:
Frontiers Editorial Office, Frontiers Media SA, SwitzerlandCopyright © 2024 Jiang, Wu, Liu, Feng, Ye, Huang, He, Shen, Zhu, Zhou, Jiang, Qi, Zhang and Yan. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Yi Yan, yannie0928@163.com; Hao Zhang, drzhanghao@126.com; Hai-Kun Qi, qihk@shanghaitech.edu.cn
†These authors have contributed equally to this work and share first authorship
‡These authors have contributed equally to this work and share last authorship